USPTO serial 79128751
ACTAVIS PHARMACEUTICALS
Reviewed by CopyMark Law Group
Reg. 4673382Status 404
- Filing date
- Status date
- Registration date
- Jan 20, 2015
- Examiner
- SNAPP, TINA LOUISE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with ACTAVIS PHARMACEUTICALS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Gabrielle S. Roth
GABRIELLE S ROTH SUGHRUE MION PLLC2100 PENNSYLVANIA AVENUE NWWASHINGTON, DC 20037-3213UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals used in industry and science, namely, active chemical ingredients for use in the manufacture of pharmaceuticals, chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; chemical preparations for use in industry | SECTION 71 - CANCELLED | — |
| 003 | Soaps; Perfumery; Essential Oils; Cosmetics, namely, cosmetic preparations for skin care, cosmetic preparations for body care, cosmetic preparations for bath and shower, cosmetic creams, lotions, and ointments and gels for skin care, cosmetic skin fresheners and toners, cosmetic preparations for the hair and scalp, and hair lotions; Dentifrices, namely, anti-cavity dental rinses, mouth rinses and mouth washes, cosmetic preparations for the care of mouth and teeth | SECTION 71 - CANCELLED | — |
| 005 | Pharmaceutical preparations for the prevention and treatment of alimentary tract and metabolic diseases and disorders, dermatological diseases and disorders, genito-urinary and sexual diseases and disorders, musculo-skeletal system diseases and disorders, nervous system diseases and disorders, respiratory system diseases and disorders, cardio-vascular diseases and disorders specifically excluding tissue plasminogen activators; pharmaceutical preparations for the prevention and treatment of sensory organ diseases and disorders, systemic hormonal pharmaceutical preparations and substances, pharmaceuticals, namely, anti-infectives, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, antiparasitic preparations and substances; contraceptives; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing preparations, pharmaceutical preparations and substances for the treatment of premenstrual syndrome, post natal depression, fluctuating hormone levels, pharmaceutical preparations and substances for infertility disorders, pharmaceutical preparations and substances for in vitro fertilization (ivf); pharmaceutical preparations in the nature of medicated dental rinses, mouth rinses, mouthwashes, dental lozenges, dental tablets and medicated chewing gum; dental wax; pharmaceutical preparations in the nature of pregnancy test kits, ovulation test kits and in-vitro ovulation prediction test kits all for home use. pharmaceutical preparations in the nature of diagnostic test kits for home use for detecting urinary tract infections, for detecting menopause, for detecting vaginal pH balances and for detecting sexually-transmitted diseases; pharmaceutical preparations for skin care; all the foregoing specifically excluding tissue plasminogen activators | SECTION 71 - CANCELLED | — |
| 041 | Educational services, namely, conducting conferences, seminars, webinars, video case studies, classes and workshops in the fields of healthcare, women's health, pharmaceuticals and medicine, pharmaceutical research and development | SECTION 71 - CANCELLED | — |
| 042 | Scientific and technological services, namely, consulting in the field of pharmaceuticals pertaining to biotechnology, product evaluation, diagnostics, testing and inspection; pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals and chemical analysis | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Actavis Group PTC ehf
- Other trademarks owned by Actavis Group PTC ehf
- Other trademarks owned by Actavis Group PTC ehf
- Other trademarks in Class 001
- Other trademarks in Class 003
- Other trademarks in Class 005
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named ACTAVIS PHARMACEUTICALS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 12, 2023 | DENC | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED | — |
| Jun 11, 2023 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Oct 22, 2022 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 15, 2022 | INNT | TOTAL INVALIDATION PROCESSED BY THE IB | — |
| Jul 20, 2022 | INTS | TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB | — |
| Jul 19, 2022 | INPC | INVALIDATION PROCESSED | — |
| Apr 6, 2022 | INTR | TOTAL INVALIDATION OF REG EXT PROTECTION CREATED | — |
| Aug 6, 2021 | C71T | CANCELLED SECTION 71 | — |
| Jan 20, 2020 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| Jun 12, 2015 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 28, 2015 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 28, 2015 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 20, 2015 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 20, 2015 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 17, 2014 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Dec 17, 2014 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Dec 17, 2014 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| May 29, 2014 | RFNP | REFUSAL PROCESSED BY IB | — |
| May 8, 2014 | OPNS | OPPOSITION NOTICE (IB REFUSAL) SENT TO IB | — |
| May 6, 2014 | OPNC | OPPOSITION NOTICE (IB REFUSAL) CREATED | — |
| Mar 4, 2014 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Oct 3, 2013 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Sep 16, 2013 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Sep 10, 2013 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 10, 2013 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 28, 2013 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Aug 28, 2013 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Aug 21, 2013 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 6, 2013 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 5, 2013 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 25, 2013 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 24, 2013 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 24, 2013 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 22, 2013 | DMCC | DATA MODIFICATION COMPLETED | — |
| Jul 22, 2013 | ALIE | ASSIGNED TO LIE | — |
| Jul 21, 2013 | ATRV | ATTORNEY REVIEW COMPLETED | — |
| Jul 16, 2013 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 16, 2013 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Jul 8, 2013 | CREV | CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED | — |
| Jul 6, 2013 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Jun 8, 2013 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 15, 2013 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 15, 2013 | RFRR | REFUSAL PROCESSED BY MPU | — |
| May 15, 2013 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| May 14, 2013 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 7, 2013 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| May 3, 2013 | DOCK | ASSIGNED TO EXAMINER | — |
| May 3, 2013 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| May 2, 2013 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |